Pharmexcil Logo Supported by: Government of India
Pharmexcil Home   l   IPR & RC Home
News : SPI Pharma Assigned Patent  |  Supernus Pharmaceuticals Inc : Supernus Pharmaceuticals Assigned Patent  |  Galectin Therapeutics Receives US Patent for Combination Treatment for Liver Fibrosis  |  Enzymotec Ltd. Granted Patent for a Lipid Preparation Use Method  |  Alkermes Announces Notice of Allowance of U.S. Patent for a Novel Fumarate Prodrug for Multiple Sclerosis  |  Teva Pharmaceutical Industries Limited : Patent Issued for Crystalline Solid Rasagiline Base  |  Lupin Limited : Patent Issued for Process for Preparing Pharmaceutical Ophthalmic Compositions  |  Antares Pharma Inc : 2 January 2014 Antares Pharma Announces Notice of Allowance for New Patent on Reconstitutable Lyophilized Injectables  |  Novartis AG : Patent Issued for Injectable Depot Formulation Comprising Crystals of Iloperidone  |  Oramed Receives Patent Allowance in Israel and Australia for Platform Technology in Oral Delivery of Proteins  |  Vaxenta Inc. Announces Filing of International Patent for Novel Cancer Vaccine  |  Glenmark faces patent suit for cancer drug in US  |  Immunomedics Announces U.S. Patent for Antibody-SN-38 Conjugates  |  FTC expands patent transfer rights reporting rules, effective December 16, 2013  |  Merck Sues to Stop Generic NuvaRing  |  Finnegan ebook summarizes various AIA considerations and U.S. patent trends in chemical and pharmaceutical industries  |  Glenmark Confirms Patent Challenge for Bendamustine Hydrochloride  |  Biotech and Pharma Update: News for December 2013  |  USPTO Issues Memo on Changes Pertaining to Patent Law Treaty  |  Drugmaker Aptalis Files For IPO After Overhaul  |  GTC BioTech Introduces Patented Handheld Device to Relieve Sinusitis and Cold Congestion With Micro-Electrical Stimulation For Immediate Release  |  Lawsuit Over NuvaRing Generic Equivalent Filed by Merck  |  Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin (RX-5902)  |  Hofseth Biocare ASA : Salmon oil patent granted in Singapore  |  Abbott forks over $5.5M to settle physician kickback allegations  |  MUSC files lawsuit against prescription drug giant for patent infringement  |  Mylan settles with Eisai in Targretin case  |  A Big Year for Pharma Deals Keeps Getting Bigger  |  New Allergan Patents May Fend Off Restasis Rivals  |  Antares Pharma® Announces Notice of Allowance for New Patent on Reconstitutable Lyophilized Injectables  |  US district court upholds ViiV HIV patent  |  ERYTECH Announces the Decision of USPTO to Extend the Additional Exclusivity Period of Its Core Process Patent to Almost 4 Years  |  Actavis Confirms Generic NuvaRing® Patent Challenge  |  Two Pharma Companies Fined Over 'Pay For Delay'; Novartis Unrepentant About Suffering Caused  |  Keryx announces issuance of new US patent for Zerenex  |  Senate Judiciary Committee Holds Hearing on "Protecting Small Businesses and Promoting Innovation by Limiting Patent Troll Abuse"  |  Pfizer allows Teva’s generic Viagra  |  Can-Fite Granted U.S. Patent for Utilization of A3 Adenosine Receptor as Biomarker to Predict Patient Response to CF101 in Autoimmune Inflammatory Indications  |  Chennai Patent Office revokes Pfizer's second patent on Detrol  |  Swiss Group Finds Patent-Related Ethical Violations By Pharma Overseas  |  RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Allowance From Canadian Patent Office For Reversal Of Skin Aging  |  Aastrom Biosciences, Inc. (ASTM) Granted Composition-Of-Matter Patent For Ixmyelocel-T In Australia  |  Acorda Therapeutics (ACOR) Announces European Patent Office Upholds Fampridine (FAMPYRA®) Patent  |  Keryx Biopharmaceuticals (KERX) Announces Issuance Of U.S. Patent For Zerenex™ Covering Orally Administrable Forms Of Ferric Citrate  |  EU Fines Pharmaceutical Giants $22M  |  European Commission welcomes continued low level of potentially problematic patent settlements in EU pharma sector  |  Chinese Patent Medicine Industry Report, 2012-2015  |  Politicians Urge Obama To Allow Public Review Of IP Provisions in TPP  |  WHO Gains From The Relentless Rise In IP Applications?  |  Global Patent filings Grow At Their Fastest For 18 Years  |  Actavis Announces Tentative Agreement Related to Asacol® HD Patent Challenge Litigation  |  Biousian Biosystems Receives US Patent for Best-in-Class Analgesic  |  Galderma Laboratories, L.P. v. Tolmar, Inc. (Fed. Cir. 2013)  |  Forty Blockbuster Drug Brands Will Lose Patent Exclusivity Between 2013 and 2020  |  USPTO Issues Final Rule to Implement Patent Law Treaty -- Changes Take Effect December 18  |  Reduce Time to Receive Filled Prescription Medication: ADVS-Technologies Patent Pending Optimization of Pharmacy Operations Using Automatic Distributed Vending System  |  Grace Announces Additional Patent Granted For Flash Chromatography Technology  |  Keryx Biopharmaceuticals Announces Issuance of U.S. Patent for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate  |  Neptune and Aker BioMarine Reach Patent Infringement Settlement and License Agreement  |  Teva settles Viagra patent litigation with Pfizer  |  Are Multiple SPCs per Patent Allowed?  |  Caris Life Sciences Receives Patent for Molecular Profiling Service in The People's Republic of China  |  Absorption Systems Awarded Japanese Patent for CellPort Technologies®  |  As GSK hails its FDA nod for Anoro, a Novartis Advair knockoff prepares for its close-up  |  Pomerantz Law Firm Has Filed a Class Action Against Turquoise Hill Resources, Ltd. and Certain Officers -- TRQ  |  Stryker agrees to settle four metal hip lawsuits as hundreds more loom  |  Stryker agrees to settle four metal hip lawsuits as hundreds more loom  |  Novartis May Face Criminal Charges In Japan Over Diovan Research  |  Mylan Settles Targretin Suit  |  GSK, ViiV: Lupin Generic Does Not Infringe Trizivir Patent  |  Indian pharma company wins patent war against US firm  |  Pharma sector seeks most number of patents in India  |  Health Care Companies Should Compete On Products, Not Patents  |  Myriad Genetics Sues Labcorp Over BRCA Gene Testing  |  Orion Settles Patent Dispute Over The Proprietary Drug Precedex(R)  |  Aeolus Files Application For New Patent On AEOL 10150  |  Mylan Holds Back $250M In Agila Buyout  |  Pfizer Fights Hanmi In Korea Over Its Viagra Design  |  Lead Attorney In US-Based Thalidomide Cases Responds To Recent $81 Million Settlement For Australian Victims  |  Idenix Files Patent Infringement And Interference Lawsuits Against Gilead Sciences  |  Amarin Announces Notification Of Patent Allowances From USPTO  |  Kalobios Receives Notice Of Allowance For Key Composition Of Matter Patent Covering KBOO4  |  Impax, Purdue Pharma Enter Into Agreement For Oxycontin Patent Challenge Settlement  |  House Passes H.R. 3309 (Innovation Act) -- Updated  |  23andme Named In Class Action Lawsuit  |  Patent Box Proposal Could Boost Pharmaceutical And Life Science IP Development And Raise US Global Competitiveness  |  Which Popular Drugs Are Going Off-Patent In 2013-2016?  |  MNCs lead in patenting of both product and processes in India after change in patent law: Origiin IP  |  Expanse Bioinformatics Receives New Patent  |  Evaluating Lilly's Dividend Prospects In Light Of Cymbalta Patent Expiration  |  South Africa: Changes Coming to the Nation's Patent System  |  Cadila Healthcare gains on settling US patent issue  |  High Court affirms that methods of treatment are still patentable in Australia  |  Astrazeneca sues Aurobindo over infringement of patent  |  Cadila, Zydus Pharma in pact with Warner Chilcott to settle US patent issue  |  Invitae Files Motion to Dismiss for Lack of Personal Jurisdiction in Myriad Genetics v. Invitae Corp.  |  EPO Clarifies Extent to which Methods Involving Use of Human Embryos Are Excluded from Patentability  |  Patent Issued for Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-B] Pyridin-3-Amine and Derivatives Therof  |  Actavis Announces Tentative Agreement Related to Asacol Patent Challenge  |  GW Pharma Gets U.S. Patent Allowance For Use Of Cannabinoids In Treating Glioma  |  EU pharma patent settlements continuing to rise  |  Teva fears profit plunge as patent on multiple sclerosis drug runs out  |  Oramed Receives Allowance on its Core Oral GLP-1 Technology Patent in Israel  |  THE DRUGS AND COSMETICS (AMENDMENT) BILL, 2013  |  Gilead HIV/AIDS Blood Booster Gets EU Nod  |  FDA Publishes Guideline Draft on the Registration of Production Sites  |  Sun Pharma to Become Sole Supplier of Cancer Drug in US  |  India’s Biocon Promises Herceptin Biosim Launch By Fiscal Year End  |  European Commission Grants Huge Funds For New Antibodies Research  |  China Launches Campaign Against Illegal Online Drug Sales  |  EMA, FDA Provide First Glimpse into Quality by Design Parallel Assessment Pilot  |  Falsified Medicines Directive Goes Into Effect in the UK  |  Malaysia Issues Guidance for Medical Devices  |  Parliamentary Panel Asks DoP to Pursue Matter of Taking Control of CDSCO  |  US FDA Seeks Applicants to Test Supply Chain Security for Drugs,APIs  |  Dr Reddy’s, Intas Eye a Pie of Indian Market For Herceptin  |  New Warning Letters to Indian Manufacturers Again Find CGMP Violations, Falsified Test Results  |  Generic Drugs Face Regulatory & Scientific Challenges  |  New Gene Patent Rules  |  Pharmaceutical, Device Recalls Spike in Second Quarter, Led by Compounding & Global Trends  |  Drug Patent Expirations  |  China’s Trademark Registration Application Fee to be Lowered Effective 1st October  |  Banned/Unapproved Drugs  |  Serum, Univ of Pune Bag US Patent for New Vaccine Adjuvant From Ashwagandha  |  India to Overhaul Foreign Pharma Investment Policy  |  FDI in Pharma: DIPP to Circulate Draft Cabinet Note This Week  |  Health Ministry Hopeful of Introducing CDA Bill, Despite Disruptions in Parliament  |  NPPA Pharmaceutical Pricing Authority Told to Fix Prices of 33 Anti-Cancer Drugs  |  Brazilian Good Practices Certification Process Simplified  |  With Recall Options Limited in Compounding Case, FDA Turns to Public Shaming to Protect Consumers  |  India Approved 26 Drugs Without Clinical Trails  |  China’s Patent Re-Examination Board Says Pharmaceutical Salts not Patentable Over Pure Compounds  |  Austria: Amendment of IP- Related Statutes Will Come Into Force Shortly  |  DCGI’s Plan to Establish Drug Audit Office in China Yet to Come up  |  Roche’s Patent Pain to be Biocon’s Gain  |  Brazil’s Anvisa to Implement Programs Improving Patient Access to Experimental Drugs  |  With New Import Rules Set to Impact Food & Supplements, FDA to Solicit Public Feedback at Meetings  |  With New Import Rules Set to Impact Food & Supplements, FDA to Solicit Public Feedback at Meetings  |  China in High Risk Regulatory Phase, According to CFDA Commissioner  |  FDA Releases Updated Draft Guidance on Medical Foods  |  Roche Won’t Pursue Herceptin Patents in India  |  Easing US Drug Spending Gives Sanofi, Novo Room to Raise Insulin Prices  |  India Considers Modifying Foreign Investment Rules to Protect Local Drug Industry  |  No Link Between Faster Drug Approvals, Regulatory Safety Warnings & Drug Withdrawals in Canada & the USA  |  European Parliament Committee Proposes Enhanced Device Reg Reforms  |  Update: List of Written Confirmation Issued by CDSCO  |  FDA Adopts Revised Blood Products Labeling Standard  |  ICH Opens Elemental Impurities Guideline for Consultation  |  Ajanta Pharma Succeeds in Revoking Allergan Patents  |  Sun Pharma to Pay Rs. 2,517 Cr to Settle Suit  |  Alembic Pharma to Add 30 Drugs in Indian Market  |  China Will Overtake Japan in R&D Spending  |  Anvisa to Open Consultation on New Traditional Herbal Product Category  |  VIANZ Merges With Medicines New Zealand  |  India Clears 12 FDI Proposals Worth $58mn  |  FDA Announces Planned Withdrawal, Revision of Dozens of Guidance Documents  |  Pharma Yet to Take Full Advantage of UK’s Patent Box, Says Expert  |  Drug Makers Get 30 More Days to Implement New Prices  |  DCGI Keen to Strengthen Regulatory Mechanism for Medical Device Sector  |  Australian Pharma Fury at 492 Drug Price Cuts  |  Despite India’s Herceptin Patent Moves, Biosimilar Rival Isn’t Imminent.  |  Pakistan: Pharma Players Express Reservation Over DRA Decision.  |  CDSCO Publishes More than 200 Written Confirmations for APIs From India  |  Draft Guideline ICH Q3H for Elemental Impurities Published  |  US FDA Goes After Another Indian Site With Form 483 for Strides Injectable Facility  |  API, Generic Drug Facilities Hit With US FDA Fee Hikes for 2014  |  SC to Examine Pharma Pricing Policy, Order on Drug Control  |  Industry Wants NPPA to Allow one Month Extension for Adopting New Prices for All  |  Commerce Ministry Plans Short term, medium Term Measures to Boost Sagging Pharma Exports  |  Pharma Department to Meet Drug Makers Today to Sort Out Pricing Problems  |  Brazil Suspends Certification Process For Foreign Bioequivalence & Bioavailability Test Centers  |  India Hits Roche’s Herceptin in Latest Blow to Big Pharma Patents  |  The FDA Oks 5 Blockbusters in Slow Start to 2013 Drug Approvals  |  FDA Issues Guidance on Qualifying for Device User Fee Exemptions, Reductions  |  Legislation Would Create New Registration, Warning Requirements for Supplements  |  Draft ICH Guideline Calls for Testing, Limits on Metal Impurities  |  US FDA Set to Release the Final Norms For Contract Mfg Arrangements for Pharma Shortly  |  GSK Pharma Loses Patent For Breast Cancer Drug Tykerb  |  Medical Devices May Skip Stiff FDI Norms  |  FinMin to Press for Re-Look at Pharma Product Categories  |  Brazil Proposes New Traditional Herbal Products Classification  |  FDA Publishes All User Fee Rates for Fiscal Year 2014  |  New Requirements of the FDA on Stability Testing of Generic Drugs  |  New & Generic Drug Approvals  |  Australia: Australia’s TGA Issues Bio similar Guidance  |  New Zealand: Medicines & Vaccines Merge to Form Single NZ Body  |  US FDA Amends Draft Guidance Documents List for 2013  |  India Asks US to Tighten Patent Regime to Curb Misuse  |  FDA Publishes ICH Q4B- Annex 13 on Density of Powders  |  Written Confirmation: A Questions & Answer Document of the Danish Authority Provides Further Clarifications  |  New EMA Inspection Requirements on Good Distribution Practices  |  China Cancels Gilead Hepatitis, HIV/AIDS Patent  |  New & Generic Drug Approvals  |  New FDA Guidance Explains Process Behind Safety Labelling Changes for Drugs, Biologicals  |  New & Generic Drug Approvals  |  Drug Patent Watch Expirations  |  US appeals court shortens patent protection for Teva\'s Copaxone  |  India Seeks to Cancel Roche Cancer Patent  |  New & Generic Drug Approvals  |  Natco Pharma gets favourable ruling for generic Copaxone in US  |  All Generic Facilities Must Re-Register With FDA Starting Next Month, Agency Says  |  Asia Kills Big Pharma Monopoly Dream  |  Drug Makers Using U.S Safety Rules to Thwart Generic Copies  |  Gene Patents at U.S High Court  |  Big Pharma’s Uncertain Future in India  |  No Changing Intellectual Property Laws: Sharma  |  DCGI to Issue First WC Certificates to API Exporters to EU Based on Accreditations  |  New & Generic Drug Approvals  |  Drug Patent Expirations  |  Mumbai to Host Pharma Convention  |  Ayush to Participate in iPHEX 2013  |  Guj Pharma Exporters Seek Govt Subsidy to Implement Compulsory Barcoding  |  Patent Expiry Hits Profitability of Top 15 Global Pharma cos in 2012, Novartis Overtakes Pfizer in Sales  |  National Regulatory Authority of India Meets International Standards for Vaccine Regulations: WHO  |  A Patent Victory Under Threat  |  Biotechnology Industry at Stake in Human Gene Patent Decision  |  MSD Glenmark Case Replay of Bayer Cipla Patent Feud  |  Court Asks Glenmark to Respond in Patent Row with Merck  |  New & Generic Drug Approvals  |  A DuPont Cargo Wrap that Keeps Drugs Cool  |  Govt Plans to set up Warehouses Abroad to help SME Exporters  |  MSF Urges India to Resist European Pressure to Trade away Health  |  Electronic Submission Program Expands into INDs for Biologics  |  European Commission Releases Harmonized UDI Framework  |  Indian Pharma Expects US FDA’s SUPAC Mfg Eqpt Addendum to Boost Global Regulatory Compliance  |  Merck Vs. Glenmark Case Revives Patent Linkage Issue  |  Gulf States See “Surge” in MNC/Local Pharma JVs: Report  |  New & Generic Drug Approvals  |  Serdia Verdict Critical for Cos Hit by Transfer Pricing Issues  |  Generic Firms Find Support From Clinton  |  Major Counterfeit Drugs Haul in US  |  Serdia Verdict Critical for Cos Hit by Transfer Pricing Issues  |  Brazil Releases Guidance on Drug Manufacturing Decontamination Validation  |  FDA Seeks New Authority Through FDASIA to Administratively Detain Deficient Pharmaceuticals  |  Is he Indian Law Hurting Innovation?  |  Sharma Defends India’s Patent Regime  |  India Allows Generics of Merck & Co’s Januvia for Now  |  New & Generic Drug Approvals  |  Pharma Industry in Haryana Seek Incentives to Revive Formulation Output, State Govt Express Inability  |  Health Ministry to Finalize Guidelines to be followed by API Units Before Exporting to EU  |  India’s Top Court Rebuffs Merck, Lets Generic Januvia Roll Out  |  Pharma Verdicts Bring Major Changes in Patents  |  Limited Impact of Glivec Decision  |  Patent Loss Pushes Lipitor to 17th Rank in 2012, Abbott’s Humira is World’s Largest Selling Drug  |  Busting the R&D Myth  |  Ever greening Clause: Thank the Left for it  |  New & Generic Drug Approvals  |  Imported Insulin Drugs May Become Costlier  |  AIDCOC Urges Indian Pharma Cos to Charge Reasonable Prices on all Generic Drugs  |  NPPA Fixes Price of Bulk Levosalbutamol  |  Specialty drugs “to account for 50% of all US Pharma Costs by 2018”  |  Exporters Urge Govt to Keep Activities of Foreign Office of Indian Firms Out of Purview of Service Tax  |  Written Confirmations: How is the EU Pharmaceutical Industry Dealing With That?  |  Brazil Proposes Electronic tracking system For Drugs  |  New & Generic Drug Approvals  |  Changes to Indian Clinical Trail Compensation Rules Expected  |  Exporters Seek Parity in excise rates for Inputs, finished Formulations to Reduce transaction Costs  |  Myths about India’s Patent Rules  |  New & Generic Drug Approvals  |  Drug Patent Expirations  |  India Will Remain Generic Pharmacy Hub of the World  |  Expert Panel Forward to Review CDSCO Approvals in 4 Cases Cited by Parliamentary Panel  |  Sanofi Adding Manufacturing Capacity in China, Vietnam  |  As Novartis Loses Glivec Bid, India’s War on Pharma Patents Threatens to Spread  |  FDA Releases Fourth Bio similar Guidance Outlining New Types of Meetings  |  We Will not Yield to Pressure to Grant Patents, says Sharma  |  End of R&D  |  New & Generic Drug Approvals  |  Drug Price Negotiation May Be Way Forward  |  Two Indian Made Anti-Viral Drugs to Hit Market in Two Years  |  Pharmexcil to Organize India Pavilion 4th Time in row in Japan  |  Supreme Court of India Judgement on Novartis Case Relating to Imatinib  |  Goodbye, KFDA: Korean Regulator Gets New Name, Decentralized Authority After Reorganization  |  Taiwan Looks to Promotion of Regulatory Science as Way to Boost Pharmaceutical Sector  |  EMA to Conduct Safety Review of EU & Nationally Approved Drugs  |  Qatar’s Pharmaceutical Market to Remain Import Dependent  |  New Powers, New Name for China’s Drug Regulator  |  New & Generic Drug Approvals  |  Patent War Gets Chronic  |  Govt Begins Work on 3 more Compulsory Licenses  |  Now, Drug Prices May be Capped at time of Launch  |  Innovate at Your Own Risk  |  Drug makers Need to Think Local in Emerging Markets, execs say  |  PHARMA Pro & Pack Expo 2013 all Set to Take Off on April 24 in Mumbai  |  Novartis Sweats Glivec Patent Verdict in India  |  WHO Approved TB Test now at a Subsidized Price  |  New & Generic Drug Approvals  |  SSIs Seek Clarification From DCGI on Status of FDCs Granted Before 1999  |  Parliamentary Panel Wants Health Min to Take up Revival of Pharma PSUs with DoP  |  India State Ups Effort to Root out Counterfeits  |  New & Generic Drug Approvals  |  Drug Patent Expirations  |  Trade Pact with EU May Imperil Indian Pharma  |  US Judges Sceptic on Deals Between Generic, Branded Drug Companies  |  Commerce Ministry Plans Pharma Alliance With Japan  |  Brazil to Expedite Review & Approval Process, Recognize Foreign Audits & Inspections  |  China’s SFDA Becomes CFDA Amidst Consolidation of Power & New Leadership  |  AstraZeneca Seles Crestor Patent Row  |  Indian Pharma Industry Seeks Policy Reforms in Indonesia  |  Expert Committee on New Drugs, Trails, ECs Expected to Complete in Few Months  |  EU Marketing Authorization Holders have 40 Days to Make Labeling Changes  |  Essential Drug Makers Can Inform & Quit  |  Health Ministry to Issue Notification on Sch H1 Soon to Restrict Use of Antibiotics  |  Health Canada Moves to Regulatory E Submissions System  |  FDA Authorized to Spend New User Fees Under Just Passed Senate Bill  |  New Information on Witten Confirmation from the EU Commission  |  New & Generic Drug Approvals  |  Generics Bite Primary Care Sales, But Specialty Drugs Soar 18.4%  |  Drug Policy Bitter Pill for Low Cost Players  |  Drug Policy to Allow Change in Price Cap Before 5 Year Period  |  Commerce Ministry may step up MAI sops to Exporters to Cope with Burden of GDUFA  |  India Has Plan to meet Europe’s new API regs  |  India must follow Codex Alimentarius standards, says 8th NIS\\\' chairman  |  Biogen Idec receives US patent covering dosing regimen for Tecfidera  |  Commerce ministry may step up MAI sops to exporters to cope with burden of GDUFA  |  MHRA Announces Expansion, Will Assume Two Additional Agencies  |  Australia Releases New Joint Replacement Reclassification Guidance  |  NOVO oral insulin shows promise in early study  |  NICE Gives Thumbs Down to Novartis Breast Cancer Drug  |  China to assist Ghana in Finding Origin of Counterfeit Medicine Influx  |  Pharma MNCs are Patently Upset  |  New & Generic Drug Approvals  |  Drug Patent Expirations  |  Karnataka Plans Venture Capital Fund For Pharma Sector  |  Generics Dampen US Drug Spending; Payers Fear Rising Specialty Costs  |  Antibiotics Crisis Prompts Rethink on Risks, Rewards  |  India Deepens Effort to Regulate Clinical Trails  |  BDR Pharma Seeks Compulsory License For Anti-Cancer Generic Drug  |  ICH S1 Draft Guidance Calls for Industry to Participate in Rodent Carcinogenicity Study  |  Brazil Introduces New Online System for Minor Changes to Package Inserts  |  Centralized Procedure to See Simplified Submission Process, Says EMA  |  Pharmexcil Urges DCGI to form committee for issue on EU Directives  |  India, Spain set to begin R&D based collaborative projects in biotech field  |  IIL, Japanese firm ties up to develop molecules  |  Roche’s Pegasys gets European expanded approval to treat HCV in children 5 years and above  |  Indian co seeks compulsory licence for cancer drug of Bristol Myers  |  Genetic provides US patent re-examination update  |  Saneron gets patent to process umbilical cord blood for therapeutic use in treating neurodegenerative diseases  |  Two New Indian Advisory Committees to Generate New Guidelines for Clinical Trials, Drugs  |  Natco Pharmas success inspires BDR pharma  |  Drug-resistant TB may spread fast  |  Drug companies raises compensation concerns  |  Novo new drug result promising  |  Lonza, Hyglos reach on global settlement agreement for endotoxin detection patents  |  Glenmark in patent challenge on Bayer skin drug  |  Glenmark confirms patent challenge for its generic version of FINACEA  |  Gujarat FDCA approach CDSCO to allot Rs.100 cr for upgrading regulatory system  |  US Government Looks to Re-Evaluate Incentives for States to go after Regulatory Fraud  |  MHRA opens new portal to help organisations developing innovative medicines, medical devices  |  DoP still examining responses of stakeholders on uniform code for marketing practices  |  GlaxoSmithKline CEO says new drugs can be cheaper  |  Domestic pharma sales grow 7.7% in February  |  EU API Law Has Drug Makers There in Panic  |  CPA Report Says Growth of API Use in BRIC Countries Exploding  |  EMA Issues Final Norms For GDP of Medicinal Products For Human Use  |  Mitsubishi Pushes Into India with Neuland API Deal  |  Generic Makers Wary About Interpol Pact With Drug Majors  |  Pharma Exports to Nigeria Surge to S307 mn  |  Major Drug makers Overcharging Users: Regulator  |  India to Establish Committees to Help Regulate Trails & Drug Approvals  |  Gov Examining the Report of Inter-Ministerial Panel on Affordable Medicines for Follow up Action  |  India Issues Revised Draft Guidance For API Exports to EU  |  EFPIA Wants EC to up Talks With Asia Ahead of New API Import Laws  |  NGOs Urge Indian Government to Reject EUs Demand  to Sign FTA Before April Deadline  |  New & Generic Drug Approvals  |  Major Companies Fund Interpol Counterfeit Drug Initiative  |  Authorities assure Biopharma Industry of Addressing Concerns on Biosimilar Guidelines  |  Indian Pharma Needs Super Generics  |  Revised EU Distribution Rules Target Falsified Medicines  |  Updated Draft Guidance Describes Process For Dispute Resolutions For Drug Products  |  Drug Patent Expirations  |  Drug makers Pledge $5.9m In Interpol’s Fight Against Fakes  |  The Feds Shouldn’t Meddle With Medical Malpractice  |  Pharma Exporters Open House Meet On Foreign Trade Policy On March 14 in Hyd  |  Activists Want Compulsory License For Cancer Drug  |  Indian Companies to Shell out Rs. 30 Lakh in Generic Drug Fee  |  Consolidation of China’s SFDA Grants Agency More Prestige, Power  |  Venus Remedies’ Meropenem Receives Market Authorization in Mexico  |  New & Generic Drug Approvals  |  Baddi Drug Firms Face Closure Threat  |  Major Units Put Their Plans on Hold at Vizag Pharma City  |  Innovations Can Grow Pharma Industry Size to $55b by 2020  |  Green Chem to Ink Pact with South African Govt For Developing Herbal Monographs  |  Imported Insulin to Cost More  |  Drugs, at What Price?  |  Health Min to Take up Unethical Marketing Practices of Pharma cos with DoP  |  List of Indian Companies/Sites Registered at USFDA as on 11th March 2013  |  New EU Labeling Requirement Adopted, Some Novel Medicines to See ‘Black Triangle’ Symbol  |  Australia, New Zealand Propose Parallel Drug & Device Monitoring System  |  India For Flexible IP Regime for Small, Medium Enterprises In Developing Countries  |  New & Generic Drug Approvals  |  DCGI Issues Revised Draft Guidelines for Issue of WC Certificate For Export of APIs to EU  |  DoP asks NPPA to Review Prices Fixed For Eli Lilly’s Insulin Bands, Revision of Guidelines  |  EMA Expects OK for 2.6% Fees Hike in 2013  |  CDSCO Issues Comprehensive List of FDCs Approved By DCGI Since 1961 till Feb, 2013  |  India Backs LDCs Request For Extension of Transition Period for TRIPS Agreement  |  Bayer to File Suit Against Appellate Order on Nexavar  |  Is Negotiated Price a Reasonable Price?  |  New & Generic Drug Approvals  |  Biosimilars: Is the Market Getting Too Much Attention?  |  Latin America & Caribbean Countries Make Strong Pitch to Strengthen Trade, Investment with India  |  Karnataka Unveils Pharma Policy; Eyes Rapid Sectorial Growth  |  Simplified Single Window Clearances for all Drug Licenses Necessary: DCGI  |  Inspections Can’t Solve Import Related API Shortage Concerns Says MHRA  |  SFDA Aims to Stimulate R&D, Accelerate Approvals & Improve Distribution Practices  |  FDA Will Continue to Allow Unapproved Drugs to Receive National Drug Code Numbers  |  New & Generic Drug Approvals  |  Generics Bite Primary Care Sales, But Specialty Drugs Soar 18.4 percent  |  DPCO Not to Disturb Existing Norms on Price Control of Patented Drugs  |  Expert Panel on FDCs Meet in Delhi to Decide on Guidance Document  |  Bayer to Move HC to Protect Patent Drug  |  China FDA Report Claims Reduced Drug Lag  |  India Sinks Bayer’s Hopes on Nexavar Patent  |  EC Health Seeks Views on GDP Norms for APIs By April End, Indian Cos See No Issues in Compliance  |  Natco Pharma Wins Cancer Drug Case  |  DIPP May Extend Compulsory Licenses Beyond Cancer Drugs  |  New & Generic Drug Approvals  |  Indian Budget Fails to Address Pharma, Biotech Concerns  |  Fewer Generics Approved in 2012 But Still a Banner Year  |  New & Generic Drug Approvals  |  Report of the Committee on Price Negotiations for Patented Drugs-released by Department of Pharmaceuticals for comments before 31st March 2013  |  Fix Prices of Costly Patented Drugs: Panel  |  Compulsory Licensing Policy Relook Raises Monopoly Concerns  |  China’s SFDA Announces Major Reforms to Drug Regulatory Process  |  India May Kill Compulsory Licensing Based on Price  |  DoP Panel Recommends Linking Pricing of Patented Drugs to Per capita Income  |  Prices of Patented Drugs Must Be Based On Per Capita Income: Panel  |  Govt Mulls Formula Based Pricing For Patented Drugs  |  US EU On Collision Course Over API Rules  |  FDA Releases Guideline Q&A on Nonclinical Safety Studies for Pharmaceuticals  |  New & Generic Drug Approvals  |  Manufacturing Continues to Undercut Ranbaxy  |  Pharmexcil Urges DCGI to form Committee for Issues on EU Directives  |  EMA Regulators Release ICH Guideline on Genotoxic, Carcinogenic Starting Materials  |  Claris Gets FDA Nod For 2 Injections  |  Approvals For Clinical Trails Decline Sharply From 529 in 2010 to 253 in 2012  |  Indian Bio Pharma Industry Divided on US FDA Draft Guidance on Therapeutic Protein Products  |  IPAB to Pronounce its Order in Bayer’s Appeal Against India’s first ever CL on Nexavar on March 4  |  Three Drugs Added to FDA Watch List  |  New & Generic Drug Approvals  |  Ranbaxy Back In Gear For Generic Lipitor Production  |  Breather for Pharma Firms as Barcode Deadline May be Extended  |  USP Plans $28 million Expansion At Hyd Centre  |  New DPCO May Include Clauses to Stop cos From Pushing Drugs as Vitamin Tablets  |  India Accounts For 20% of Generics Produced Across Globe: Minister  |  GPMA Wants NPPA to Relax 10% Ceiling on Formulation in Coming Budget  |  Warning Labels Soon On All Medicines  |  Canada Implements New Labeling Update Process For Generics  |  FDA Draft Guidance Aims to Clarify Difference Between Recalls & Removals  |  Brazil’s ANVISA Issues Water Purification Norms For Pharmaceuticals  |  Herbal Sector Object to Draft Norms For Patenting of Traditional Knowledge  |  Ranbaxy to resume generic Lipitor production for US  |  Pharma Exports Expected to Touch Rs 75,000 Crore in 2012-13  |  New European patent court to be built in London  |  Pharma Firms May Have to Share Drugs Production Details With Govt  |  India & Bangladesh Sign MoU On Health  |  Kazakhstan Government Plans To Build Biologics Plant  |  New & Generic Drug Approvals  |  Exporters Upset Over Govt’s Delay in Convincing EU to Accept Indian GMP on Par with EU CGMP  |  Pfizer to Appeal Patent Decision on Caner Drug  |  Indian Generics In Need of Policy Tonic  |  Dr Reddy’s Declares Octoplus Offer Unconditional  |  UK Regulator Concerned Over Increase of Illegal Eastern European Drugs  |  ICH Photo safety Guidance Aims to Bridge FDA, EU Differences  |  CDSCO Oversight Plan For APIs Shipped to EU Published by Pharmexcil  |  Nigeria, Algeria Offer Excellent Export Opportunities For Indian Pharma Cos: Appaji  |  Novo Nordisk Hit as US Seeks More Insulin Drug Trails  |  Fake Drugs Thrive In Indian Mart  |  Sun Calls It Quits In 6 Year Effort to Swallow Taro  |  Pfizer May Value Strides Unit at Rs.10k Cr  |  Barring the Way of Fake Drugs  |  Cipla Puts Medpro Buyout On Hold Over Valuation Issues  |  Govt Forms Panels to Frame Guidelines & SOPs for Approval of New Drugs, Trails, Banning Drugs  |  New & Generic Drug Approvals  |  Uncertainties Abound In Indian Draft Clinical Trail Amendment  |  The bitter sweet policy on Insulin Pricing  |  New & Generic Drug Approvals  |  Pharmexcil Invites Comments From Industry on EU Directive Notification  |  Pfizer Likely to be Broken up Into 2 Different Entities  |  Meds From Foreign Plants Complicate Counterfeit Search  |  Indian Patent Agent Examination, 2013 going to be held during 4th-5th May, 2013-Last date for application 25th Mar, 2013  |  DCC Meet Discusses Major Issues Pertaining to Implementation of D&C Act  |  OPPI Demands Cut In Customs Duty On Life Saving Drugs, Medical Devices In Union Budget  |  Sun Pharma Gets FDA Nod For Cancer Drug  |  Italian Regulators Call For Clinical Data to be Disaggregated By Gender  |  New & Generic Drug Approvals  |  Drug Patent Expirations  |  India, Scotland Join Hands At Bangalore India Bio  |  Panacea Biotech Joins Bestech to Develop Township In Gurgaon  |  India, Africa Swamped By Fake TB Drugs, Says Study  |  Indian Drug Majors: “20%+Growth In 2013, Driven By Exports  |  New Law to Ensure Adequate Compensation for Drug Trail Victims In India  |  China Orders Foreign Drug Companies to Designate Local Agents  |  FDA to Release Long Awaited Guidance on CMO Agreements, Biosimilars in 2013  |  New & Generic Drug Approvals  |  Victoria Is On Mission to Tap The Indian Market  |  India Woos Iran With Its Affordable Generic Drugs  |  Indian State of AP Signs MoU With Korean Tec park  |  CDER Agenda Foreshadows Release of Guidances Long Sought by Industry  |  Lupin Lines Up Six Products For US Market  |  New & Generic Drug Approvals  |  Patent Cliff II: Nightmare on Blockbuster Street Returns in 2015  |  $19bn Worth Biologics to go Off Patent In US this Year  |  Packaging is Manufacturing or Services  |  Emcure, Roche Face Flak On Drug  |  India’s Potential Lures Pharma MNCs  |  Growing Chinese Clout In Vaccine Mart Gives Indian Players Jitters  |  Biosimilars to Boost India’s Growth Prospects In The Next 5 Years  |  BioAsia 2013, Attracts Regulators From Across The Globe  |  Pharma Firms Failing to Launch Drug In Six Months of Approval Could Lose License  |  Indian Regulator Cracks Down On Banned Drugs  |  India Aims to Clock USD 15.5bn Pharma Exports in FY 13  |  Indian Pharma to Get Speedy Approvals With US FDA’s New Safety Reporting Rules for INDs & BA/BE Studies  |  China Plans to Fast Track High Priority Generics, Other Drugs  |  Lupin Receives US FDA Approval To Market Generic Lutera Tabs  |  Aurobindo Gets Nod For Anti-Bacterial Injection  |  Final Hearings In Bayer’s Appeal Against India’s First ever CL On Nexavar to Begin at IPAB Soon  |  Increase in Imports Causes Worry For Domestic Ayush Industry  |  GAAMA to Meet Drug Regulators to Discuss Issues Relating to Manufacturing of Liquid Oral Product  |  Pharma exports to see 25% growth this year: Pharmexcil  |  Biosimilars to replace 70% of chemical drugs in 2 decades  |  Pharmexcil says drug cos need Govt help to compete with China  |  CDSCO Says Local Authorities Improperly Approving New Drug Products  |  EC Releases New Good Manufacturing Practices Guidelines  |  FDA Approves New Flu Vaccine with Potential Biodefense Applications  |  Indian pharma to get speedy approvals with US FDA\\\\\\\\\\\\\\\'s new safety reporting rules for INDs & BA/BE studies  |  New & Generic Drug Approvals  |  NuPathe wins FDA nod for Migraine skin patch  |  India Inc tops growth in R&D investments, says EU report  |  Drug Controller to Certify all Pharma Exports to EU  |  Canada to Speed up Reviews of Generic Medicines  |  Health ministry issues draft Guidelines on good distribution practices for pharma products  |  India\\\'s vaccine prices soar as private companies gain ground  |  Merck Sharp, GSK cervical cancer vaccines under scanner  |  China to Cut Prices of More Than 400 Drugs by Average 15%  |  EMA raises drugmaker fees and plans rejig  |  New & Generic Drug Approvals  |  Australian, New Zealand Regulators Lay Out Framework for New Regulatory Agency  |  Biocon gets nod to market psoriasis drug in India  |  Biotech industry gives birth to an angel to boost investment for new deals  |  China hits Big Pharma meds with 15%-plus price cuts  |  Govt plans new legislation to take DPCO out of Essential Commodities Act ambit  |  India to exhibit greatest surge in flu vaccine demand over next decade Global Data  |  Malaysia\\\'s location, domestic market draw Ranbaxy, Cipla, others  |  New & Generic Approvals  |  Pharmexcil asks AP drug control dept to discontinue country-specific issuance of CoPP  |  South Africa pharma market to grow 5.8%year to 2020  |  Indian Science, Technology and Innovation Policy 2013  |  Exporters ask DCGI to take up Falsified Medicines issue with EU to accept Indian GMP as equivalent of EU CGMP  |  FDA Approvals of 2012  |  Goose launches online and offline 2D Bar coding solution  |  Indian pharma companies secure 178 ANDA approvals from US FDA in 2012  |  Cooperative Patent Classification System Launched  |  AP bulk drug ind seeks nod for expansion  |  Apex court Stop using Indians as guinea pigs  |  Approval rate for biologics drop in India  |  Drugmaker Hub Hit as Power Gap at Six-Year High Corporate India  |  Drugs banned abroad may still be of use in some cases  |  Indian drug majors to supply life-saving medicines to Iran  |  Patents in the cause of development  |  Pharma Deals North of $10 Billion Seen Returning in 2013  |  Wockhardt launches lamotrigine tablets for treatment of epilepsy in US  |  MHRA calls global API industry to ensure adoption of Directive 201162EU for the EEA nations  |  Regulatory hurdles dampen MNC appetite for pharma buyouts  |  100 cr more for Ayush promotion  |  Prices double as private vaccines flood market  |  Drug makers slam Pak move to ban Indian products  |  Circular - Repeated with Revised Fee Particulars - Certificate Course on IPR (Patent) Matters - Five day Workshop at Hyderabad  |  IPC to add 72 more new reference substances to IP by March, total to be 250  |  Supreme Court pans government for denying data on clinical trials  |  30 Years Later, FDA Looks Back on Passage of Orphan Drug Act  |  Big Pill  |  EMA Releases Revised Draft Guideline on Pediatric Regulation  |  Its raining expansions and JVs in China!  |  Barcoding of drug packages kicks in  |  In Shift, FDA to Require eCTD for all NDA, ANDA, BLA and IND Submissions  |  Indian Pharmacopoeia Commission publishes compliance guide  |  Pakistan bans import of APIs from India  |  Firms will have to tackle regulatory challenges  |  Iran keen to import essential drugs from India to meet current shortage  |  US FDA issues guidance for clinical site data for inspection of new drug applications  |  Aurobindo gets USFDA nod for migraine drug  |  NPPA Revises Prices of 33 Formulation Packs Including Monocomponent Human Insulin By Eli Lilly  |  Suven Life Gets 3 Product Patents For NCEs In Eurasia & Canada  |  US FDA Approves Mylan’s Phenytoin Chewable Tablets  |  USFDA approves new TB drug, first in 40 years  |  ICH Vets Another Pre-Step 2 Q3D Draft to Strengthen Consensus on Heavy Metal Standards  |  Madras HC dismisses petition against barcoding, paves way for its implementation  |  Exporters lose huge orders as DCGI disallows old bulk drugs as they are not in approved list  |  Draft Guidelines for Examination of Biotechnology Applications-Indian Patent Office  |  Who gains-who loses in the new pharma policy?  |  Bar coding on pharma items packaging may be postponed  |  DCGI to meet DCC members in Feb to discuss major regulatory issues  |  Edge for large players  |  Import of pharmaceutical ingredients  |  India to open first drug inspection office in Beijing  |  Pharma Industry growing at 25% to catch up the export target by 2015  |  Pharma industry to grow five-fold over next 7 years  |  Pharmexcil, AP govt draw up plan to promote export of Unani products in key markets  |  Pharma exports to miss USD 25-mn target deadline by a year, Pharmexcil expects to achieve the target by March 2015  |  Slow Pace Of Capacity Building In Pharma Sector Cause For Concern  |  Now China Turns The Heat On India Vaccine Makers  |  DCGI Releases Guidance Manual for Compliance of Indian Pharmacopeia For Stakeholders  |  Generic Drug Application To Cost Rs.30 Lakh In US  |  FDA Releases Long Awaited Draft Guidance On Clinical Trails  |  EMA Publishes Draft Guideline On Biosimilar Insulin Products  |  Pharmexcil Seeks Extension of Bar coding Implementation For Secondary Packing By 6 Months  |  European Fine Chemicals Group Insists For Compulsory Auditing of API Units In India & China  |  Pharmexcil To Impart Certificate Course On IPR Matters From Jan 21-25 In Hyd  |  Aurobindo Gets Final Approval For Abacavir Tablets  |  Pharma Cos Promote Indian Generics In Global Market  |  New & Generic Drug Approvals  |  U.S Branded Sales To End 2012 With 3.5 percent Decline  |  Brazilian Regulatory Authorities To Expedite Minor Labeling Changes  |  Biocon Partners Chemical Company Of Malaysia For Insulin Distribution  |  Gujarat Pharma SMEs Bet On Africa, LatAm For Exports  |  Panacea Gets Bulk Govt Order For Polio Vaccines  |  Sun Pharma Buys URL Generic Biz From Takeda  |  Pfizers Sutent Patent Case Against Cipla Adjourned  |  DCGI Reiterates Stand On Grant Of Product License In Genric Names Only  |  WHO Endorses Vaccine Regulatory System In India After Inspection  |  Comprehensive Online Filing Services For Patents Inaugurated  |  New & Generic Drug Approvals  |  World Pharma Trade Centre Planned At Hyderabad  |  iPHEX 2013 To Showcase On Indian Pharma Exports; R&D Capabilities  |  China Major Supplier Of APIs To Indian Pharma Companies  |  Pfizer Seeks To Prevent India’s Cipla From Selling Cancer Drug  |  MHRA Issues New Procedure To Speed Up Shift Of Drugs From Prescription To OTC  |  Gujarat FDCA Enters Into MoU With MHRA To Focus On Cross Training Activities  |  Officials From Commerce Ministry DCGI’s Office Meet Up MHRA Officials In Delhi  |  Indian Vaccine Industry Passes WHO Quality Test With Flying Colours  |  Jan 2013 Deadline For 2D Barcoding At Primary & Secondary Level To Stay  |  New & Generic Drug Approvals  |  U.S. Congress passes bill to move U.S. closer to international design patent application system  |  Certificate Course-Pharma IP (Patents) in International Trade during 21st-25th Jan 2013 at Hyderabad  |  India Revokes Patent On Merck & Co Asthma Drug  |  PSM Says China Counterfeit crackdown Starting To Work  |  MHRA Says 1,200 API Plants May Need Inspecting Under New Import Laws  |  Pharmexcil’s Buyer-Seller Meet During IPC Attracts Large Number of Buyers & Sellers  |  Health Ministry’s Notification “Limiting of Paracetmol” To 325mg For All FDCs Create Confusion  |  New & Generic Drug Approvals  |  Drug Patent Expirations  |  India-Iran Finalize Rupee As Trade Currency  |  GDUFA Self Identification Plan Not Flawed Says SOCMA After FDA Extends Deadline  |  Centre To Spend Rs. 6000cr In 12th Plan For Various Programmes To Make India Free From Spurious Drugs: DCGI  |  CDSCO Launches Special Drive To Ensure Quality Of Drugs Across Country  |  Pharmexcil To Hold Buyer Seller Meet On Herbals, Ayurveda Products During World Ayurveda Congress In Bhopal  |  MHRA Launches Procedure To Speed Up Drugs Transfers From Prescription To OTC  |  Govt Issues National Pharmaceuticals Pricing Policy 2012  |  New Drug Policy To Cut, Cap Prices Of 650 Common Drugs  |  Indonesian Pharmacopoeia To Adopt & Adapt USP NF Standards  |  Opportunity in Myanmar  |  Protecting well-known trademarks proactively-India  |  Getting patent claims accepted: procedural issues-India  |  Punjab Plant May Be Cause Of Ranbaxy’s Lipitor Drug Recall  |  FDA Registration Deadline Looms For Generic Drugmakers  |  FDA Matches Most New Drug Approvals In Years In 2012, But Is It Enough?  |  Natco Looks To Launch Lansoprazole In US  |  India-Business methods and software patents  |  Recent developments in data protection regulations-Mexico  |  Driving down the cost of medicines-Ireland  |  India To Explore Potentials To Iran In The Backdrop of Recent UN Sanctions  |  India Bureaucrats Decide To Review All Foreign Pharma Investments  |  Orchid Hospira $200m Deal Hits A Roadblock  |  GDUFA Self Identification Plan Not Flawed Says SOCMA After FDA Extends Deadline  |  Novartis Glivec Case Poised For Final Verdict  |  CDSCO To Place 91 Drugs Under Schedule H1 To Rationalize Use of Antibiotics  |  Pharmexcil To Represent India Pavilion At Arab Health 2013 In Dubai  |  UK MHRA To Sign MoU With 3 State FDAs  |  Drug Patent Expirations  |  The draft regulations on service invention published for comments-China  |  Supreme People’s Court highlights over-all observation principal in a design patent invalidation case-China  |  India Medical Devices Marketed To Touch $11 bn By 2023  |  Policy May Hurt, But Street Is Not Worried  |  USP Details New Drug Naming Scheme  |  Supreme Court To Review Key Generic Drug Case  |  FIPB To Vet Pharma M&As Involving FDI  |  Govt Nod Must For FDI In All Existing Pharma Projects  |  List of WHOGMP/USFDA/MHRA/EDQM approved Indian Companies/Products  |  State Drug Controller’s Concerned Over DCGI’s Clarification Over Issue of Sec 33 (p)  |  EMA Set To Revise Annex 15 of GMP Guide, Seeks Industry Comments Before Feb 2013  |  PM TO Finalise FDI In Pharma  |  New Drug Pricing Set To Change Industry  |  Gov Has Little Role In Controlling Prices of Patented Drugs  |  Indian High Court Tells Patent Office To Re-Weigh Pfizer’s Sutent  |  Strides Arcolab Receives US FDA Approval For Ifosfamide Inj  |  Prices of Branded Drugs Rise Sharply  |  Astrazeneca Drug Appeal Dismissed In Blow To Big Pharma  |  GSK and J&J lead rivals in drug access for poor  |  Branded Drug Prices Leap 13% In US Far Outpacing Inflation  |  China Fosters Biosimilar Drug R&D With New Set of Custom Guidelines  |  State FDAs Differ On Use of Brand Names In Licenses  |  Chaos Prevails Over Granting of Licenses In Brand Names For Export Purposes  |  Commerce Ministry Not To Withdraw Implementation of Barcode On Pharma Exports  |  Drug Patents Expiry  |  Pharmexcil To Conduct Intl Business Met On Sidelines Of IPC To Expand Business Opportunities of Indian Exporters  |  EC Makes Switzerland Exempt From API ‘Written Confirmation’ Requirement  |  EC Asks Pharmas How Long To Add ‘Black Symbol’ To Risky Drugs  |  Ranbaxy Launches Absorica Capsules In US Market  |  Indian Diabetes Market Revenues To Reach $1.49bn By 2016  |  Lupin Unveils Generic Tricor In US Market  |  CGPDTM extends last date for submitting comments on the draft “ GUIDELINES FOR PROCESSING OF PATENT APPLICATIONS RELATING TO TRADITIONAL KNOWLEDGE AND BIOLOGICAL MATERIAL” to 29th November 2012. There will be no further extension  |  CGPDTM invites proposals for providing (i) access to patent database & interface; and (ii) developing a customized integrated search platform and related interface. Deadline for submission of proposals: 28th December 2012  |  GoM On Drug Pricing Policy To Meet On Wednesday  |  US FDA Adopts ICH Q11 On Drug Substance Manufacturing  |  Marinomed Granted Chinese Patent For Cold Virus Fighting Polymer  |  India Will Back Pharma SMEs In $500m Finance Scheme  |  Brazil Wants To Buy Pharma Tech From The Ukraine  |  Top 20 Generic Molecules Worldwide  |  Commerce Ministry’s Intervention Sought To Stop Enforcing Barcodes On Pharma Exports  |  NPPA Cuts Price Of Diabetic Drug Glipizid, Hikes Rate of 4 Other Bulk Drugs  |  Lupin Launches Fenofibrate Tablets In US  |  Drug Price Policy: FM To Meet Minister’s Panel Today  |  Biocon Protests Dual Pricing Method of NPPA For Insulin  |  Regulator Caps Insulin Prices  |  Dr Reddy’s Launches Sildenafil Tabs  |  Vibrant Gujarat 2013 To Focus On Knowledge & Networking  |  Panacea Biotech Announces Strategic Alliance With Kremers Urban  |  Drug Patent Expirations  |  Recent developments in data protection regulations-Mexico  |  Indian Patent Appellate Board confirms that NGOs can oppose patents after grant in India  |  Requirement for PCT filing (National Phase entry in India)  |  India - FAQ’s on registering your brands  |  Going above and beyond-The Indian courts have gone beyond the text of the statutes to protect the worldwide reputation that any trademark or commercial sign can acquire by virtue of its use, promotion or advertisement  |  Cipla Buying Control Of South Africa’s 3rd Largest Drug Maker  |  Pharma Exports To Touch USD 25bn By 2014-15  |  News From The PIC/S  |  Decoding The National Pharma Pricing Policy  |  Drugs Soon To Have Only Generic Names  |  MHRA Consults CROs On European Commission’s Revision On Clinical Trials Regulation  |  NPPA’s Attempts To Recovered Overcharged Amounts Through District Collectors Also Fail To Push Up Recovery From Pharma Cos  |  DCGI To Be Competent National Authority To Certify API Exports To EU  |  India Needs Market Based Drug Pricing, Govt Urged  |  Patent Filing India  |  India - FAQs on trademark oppositions  |  Government pledges No more counterfeit software  |  Filing requirements designs-India  |  Filing requirements trademarks-India  |  Curing medicines There is more to cheap drugs than price control  |  CSIR To Begin Clinical Trail For TB Drug Soon  |  ‘Side-effects’ of prescription for cheaper medicines  |  Price Cap For Non Scheduled Drugs May Go Up From 10 To 15% In New Policy  |  DCGI To Meet Zonal Officials To Re-Examine Regulatory Requirement For Vaccines  |  EU’s Falsified Medicines Directive Puts Indian Cos On a Spin, Center Gears Up For Action  |  Industry Conducts A Meeting With Ministry On 2D Implementation  |  Is The Shift Away From Cost Plus Drug Pricing Desirable?  |  IP monetisation in India: exploring the options  |  Not so fast, China – ABA sections submit comments on intellectual property-related provisions in China’s draft anti-monopoly law  |  Chinese courts on liability of e-commerce sites relating to counterfeiting through their platforms  |  Redefining the role of the IP steward  |  Drug Pricing GoM May Meet FM To Clear Standoff  |  CCI To Vet Brownfield Pharma M&A Deals  |  Legal Spend Up As Drug Cos Take On MNC Peers  |  Indian Regulations Will Hike Costs But Market Will Remain Competitive , Government Tells IPT  |  EFCG Wants Mandatory Inspection Of All API Suppliers  |  Call For Counterfeit Drug Treaty Gets Group Banned From WHO Event  |  Health Ministry Issues Clarification On Its Earlier Direction On Licenses In Generic Names Only  |  AP DCA Refuses To Follow Union Health Ministry’s Direction On Issuing Drug Licenses In Generic Names Only  |  Parallel Import License Granted In Aug 2012  |  Court of Appeal upholds a drug-related patent infringement claim  |  WHO fake drugs meet bars experts after India’s objections  |  South Asia’s Largest Pharmaceutical Event In Mumbai  |  Confusion Prevails Over Granting of Licenses In Brand Names By SLAs For Exporters  |  Concerns Put Pharma Policy Back On GoM Table  |  Prescribing The Right Rules For Pharma  |  UK: Marketing Authorizations Granted In Sep 2012  |  Push for change in the IP policies of standards-setting organisations  |  Patentability of human embryonic stem cell-related inventions-Germany  |  Court of Appeal upholds a drug-related patent infringement claim-Malaysia  |  Bristol-Myers Squibb obtains prohibition order against Mylan regarding efavirenz  |  New administrative measures allow for accelerated patent examination-China  |  Court declares European patent partly invalid in landmark ruling-Denmark  |  Pfizer ends deal with Chesco firm, walks away from big investment  |  10 Top Women in Biotech 2012  |  The drug industry doesnt work  |  China’s proposed amendment of patent law aims at reinforcing administrative protection of patent  |  Protecting Australian innovation: is China on the list?  |  Breather For Cipla As SC Lifts Bar On Cancer Generic  |  Pharma MNCs Get Stringent On Market Practices  |  Domestic Pharma Sales Improve In October  |  Pharma Firms Quit AP For Greener Pastures  |  Prescribing The Right Rules For Pharma  |  Japan Seeks Details From India On Unreasonable Delay By PMDA To Speed Up Registration of Medicines  |  Pharmexcil Spells Out Clarifications From MoH & FW  |  China: Electronic Monitoring Network For Imported Drugs  |  PAK: President Ratifies Bill On Drug Regulatory Body Tribune  |  Patent Expirations  |  China: RAPS SFDA To Collaborate On Regulatory Training  |  India’s CDSCO Wants Quicker Drug Recalls  |  ICH Working To Clarify Q7 For Regulators  |  Notice 2012-39 provides new rules for outbound transfer of intellectual property  |  Supreme Court of Canada releases the Viagra decision  |  Supreme Court of Canada finds Viagra patent unenforceable  |  A new Competition Act-Maldova  |  Do the AIAs changes to patent laws best mode requirement open the door to best mode trade secret protection  |  Proposed changes to design law-United Kingdom  |  Watch your assets part two: best practices for protecting confidential information  |  CGPDTM publishes draft Guidelines for processing of patent applications relating to traditional knowledge and biological material for comments/suggestions  |  Sun Pharma To Acquire US Firm For Rs. 1,250cr  |  Acquisition Brightens Sun Pharma’s Glow  |  Cipla Cuts Prices of Three More Cancer Drugs  |  African Raids Seize 82M Doses of Counterfeits  |  India’s Health Expenditure Will Rise 3 Fold  |  NPPA Issues Internal Guidelines For Price Fixation/Revision of Bulk Drugs Under DPCO, 1995  |  India Sets Up Information Cells In Many Countries To Promote Ayush  |  Novartis Targets 14 Blockbusters By 2017  |  New & Generic Drug Approvals  |  Green IP - a new way to blossom  |  Indian Patent (Amendment) Rules-2012-Relating to Patent Agent Examination  |  Central Government revokes Patent No. 252093 under Section 66 of the Patents Act, 1970  |  Barack Obama’s Re Election May Boost Indian Generic Companies  |  Pfizer Arthritis Drug Wins Approval  |  Drug Trade Margins Not Hefty  |  DoP To Commission Study On Non Tariff Barriers Facing Bulk Drug Exports, Especially In Europe  |  New & Generic Drug Approvals  |  India’s Price Setting Agency Prepares For Plant Inspections  |  Patent Expiration Hit Sales, Profits of Top 10 MNC’s In 9 Months Of 2012, Novartis In No 1 Position  |  Pharmexcil Expects Ministry Notification On Branding For Drug Exports Within A Week  |  New & Generic Drug Approvals  |  Sun Pharma May Make $320 mn Provision  |  Cipla Surges 4.1% To Record As FDA Approves US Sales  |  Drug Exports Under Brand Name To Stay  |  Indian Pharma Industry May Be Among Top Markets By ‘20  |  India Strips Patent From Roche’s Hep C Drug Pegasys  |  CDSCO Drafts Guidelines On Recall & Rapid Alert System For Drugs Including Biologicals & Vaccines  |  New Generic Approvals  |  Hepatitis C Drug May Trun Cheaper As Roche Looses Pegasys Patent  |  Mexico Eyes Investments From Indian Pharma, IT Companies  |  NZ & Taiwan Join PIC/S; API Inspection Scheme Makes Progress  |  Why the move to ban branded generic drugs is imprudent  |  Commerce Department Sets Up Consultative Panel To Push Pharma Exports  |  Industry Asks DCGI To Extend Validity of CoPP From 2 To 3 Years  |  India’s Poor Possibly Used In Illegal Drug Trails Without Their Consent  |  Health Ministry’s Order On ‘Drug Licensing Only In Generic Names’ Not Applicable To Exporters  |  Drug R&D Collaborations In china Flower As Big Pharma Focuses On Asia  |  Non EU Regulators Can Use EMA/FDA Data For API Export Letters  |  Top 15 Drug Patent Losses For 2013  |  The Intellectual Property Appellate Board (IPAB) on November 02, 2012 revoked Roche Pegasys in a post-grant opposition filed by Sankalp Rehabilitation Trust  |  Health Minister To Withdraw Licenses Issued To More Than 200 Irrational FDCs  |  PIC/S Ukraine Meeting Report  |  Insulin Is Becoming Important For Us  |  Non-EU Regulators Can Use EMA/FDA Data For API Export Letters  |  Protect your intellectual property rights in Myanmar/Burma - key steps to take now  |  EMA Wants Type I MA Variations Before End of November  |  Pharmexcil Asks Health Ministry To Exempt Drugs For Exports From Generic Licensing  |  Tips regarding trademark protection in Japan  |  Health Min’s Move On Registering Drugs May Weed Out Many Brands  |  Longer Wait For Indian Generic Launches  |  Pharmexcil Fears Order To Endorse Only Generic Name In Product Licenses To Hit Exports Badly  |  CIPMMA Adopts Resolution Opposing DCGIs Order Seeking To Stop Brand Based Licensing  |  Novartis: Compulsory Licenses Will Not Expand access To Drugs  |  Italian, Swiss, Spanish Regulators Ban Sale of Novartis Flu Vaccines  |  NHRC Panel To Frame Drug Trail Norms  |  Overcharging Pharma Cos Will Have To Shell Out Sales Revenue: NPPA  |  Genetic Drug Makers Must Pay Up To $51,520 An Application In US  |  FDA Group Argues For Helping Poor Countries Beef Up Oversight  |  Under Joint Research Programme, India & Germany To Support Research Groups of Both Countries  |  Illegal Medications Seized In 16 African Countries  |  FDA Works With Partners To Establish Important Therapeutic Area Data Standards  |  IP Australia announces a reduction in PCT fees  |  Federal Register Notice: Generic Drug User Fee--Abbreviated New Drug Application, Prior Approval Supplement, and Drug Master File Fee Rates for Fiscal Year 2013  |  Federal Register Notice: Generic Drug User Fee--Backlog Fee Rate for Fiscal Year 2013  |  EMA Sets Out Clinical Guidance On Trail Data Publishing  |  UK Patent Laws Hamper Generic Development In UK According To IPO  |  Low APIs & Excipient Volumes Vital To Win Authorization Under EU PIP Says EMA  |  EU Pushes Forward With Get Tough API Import Rules  |  EU Parliament Approves EU-Israel Medicines Trade Pact  |  Canada’s New GMP Rules For API’s  |  Parallel Import Licenses Granted In Sep 2012  |  A revised patent law in China in the works: stronger patent enforcement in the future?  |  China: New administrative measures allow for accelerated patent examination  |  Government expropriation of patents – more drugs to combat HIV/AIDS and Hep B in Indonesia  |  Compulsory licenses for emergency drugs for developing countries  |  US FDA Issues Guidelines For Packaging of Test Batches For ANDA, AADA  |  Brazil: Patents Practice Area Review  |  Pharmexcil To Approach Govt Over Central Directive To Issue Product Licenses In Generic Names  |  Central Order To Issue Licenses In Generic Names May Be Challenged In Court  |  Expert panel on \\\'new drug approvals\\\' to submit report in two weeks  |  TN pharma bodies to approach health ministry for clarity in proposed change in product licensing  |  Australia Launches Review of Pharma Patent Extensions  |  Pharma Industry Frowns At Govt’s Move On Grant of Product Licenses In Generic Names  |  Public Consultation: Transposition of Directive 2011/62/EU ( The Falsified Medicines Directive ) Into UK Legistation  |  Ministry of Commerce & Industry, GoI, Urges Indian Pharma Cos To Explore Non Regulated Markets  |  Will The Next Block Buster Emerge From Asia  |  EU Agrees To Give Observer Status To India On Issue Of THMPD  |  India Patent Authority Has Big Pharma Worried  |  Patently Against Public Health?  |  Govt May Hike Financial Benefits To Exporters Under MAI & MDA schemes To Cope With GDUFA  |  Drug Pricing Policy To Hit MNCs Hard  |  Cipla Defends Strict Patent Laws  |  Health Minister Plans Revision Of Sch P To Include New Drugs Currently Marketed  |  Pharmexcil to focus on reviving exports to EU in the aftermath of THMPD enforcement  |  Pharma Manufacturers At CPhI, Like Ash Stevens, Forecast Growth  |  Australia To Launch Consultation On Development of eCTD Guidelines, Timeline  |  Priority Review Approved Drugs Show Significantly More Problems Post-Approval  |  Commerce Ministry Initiates Efforts To Remove Hurdles Before Pharma Industry  To Achieve $25 bn Exports By March 2014  |  Data Exclusivity For Biologics At Forefront of International Trade Agreement Negotiations  |  Millions of Counterfeit & unlicensed Drugs Seized During Worldwide  Crackdown  |  Brazil’s Anvisa Addressing Drug Approval Priorities  |  Amendments To EU Pharmacovigilance Legislation Call For Additional Safety notifications  |  India Revokes Patent For Pfizer’s Sutent  |  India’s Vaccine Market To Grow To $871M By 2016  |  New FDA Staff Policy Manual Defines “Major Amendments” To Generic Drug Submissions  |  FDA Sets Deadline For Submission Of GDUFA Information  |  Biting The Price Bullet On Medicines  |  Pharma exports target of $25b by 2014-15 is tough  |  Pharma Industry Need To Look Sustaining Growth Post 2015 When Patent expiries Stops  |  FRAND and other patent licences  |  Tackling Pharmaceutical Counterfeits: Beyond Packaging  |  Essential Drug Prices To Come Down By 20%  |  EMA To Allow Biosimilar Applications To Reference Data From Products Approved Outside EU  |  348 Vital Drugs To come Under Price Control  |  President Obama Signs Into Law Three Bills Affecting FDA  |  New Report Calls For Overhaul Of Regulatory Processes With Goal Of Doubling Drug Approvals By 2027  |  Australia Implementation Prior Approval For Minor Variations  |  New Draft Stability Guidance Calls For Use of ICH Standards  |  Drug Units May Be Asked To Submit Compressive Data To SLA’s For License  |  Indian Gov To Setup ‘Competent Authority’ To Oversee API’s Shipped To EU  |  Bayer’s Plea Against Natco Dismissed  |  India Needs Strong Monitoring, Not Control System  |  The Global Innovation Index 2012-WIPO  |  EMA Updates Its Fee Structure Guidance  |  Anvisa Issues New Technology Regulation For Local Companies  |  Patent Expiries: Dr Reddy’s, Lupin To Foray Into Specialty Pharma, Aurobindo Pharma To Focus On Services  |  Indian Supreme Court Begins Final Hearing On Glivec Patent Case  |  Indian Pharma Patent Cases “misinterpret IP Records”  |  FDA Gives Generic Drug ‘Super’ Status  |  Questel offers 10 day free trial ‘Orbit patent database’ to Pharmexcil members  |  Japan: PMDA Provides Updated Guidance On Conducting Global Clinical Trails  |  Extension of Last Date for receipt of application for Pharmexcil Export & Patent Awards 2011-12  |  Seminar on IPR & Regulatory Matters in Pharmaceutical Sector at Chennai on 24th August, 2012 (Friday)  |  Commerce Ministry to discuss issues on non-tariff barriers in pharma industry with US and EU  |  Indian Regulators Release Draft Clinical Trail Rules  |  India, China plan to jointly oppose EU regulation on API at WTO forum  |  New Bill Would Expand Access To Investigational Drugs & Devices  |  Indian pharma companies like Aurobindo and Glenmark set to gain from USFDA nod for asthma drug  |  Pharmexcil to celebrate its 8th annual meet from Sept 26 - 28 in Hyderabad  |  Generic savings tell a different patent-loss tale  |  New & Generic Drug Approvals at USFDA  |  Awards for companies who secured patents during April 2011-March 2012  |  Pharmexcil Seeks Clarity from USFDA on New Drug Fee Norms  |  Lupin Gets Nod To Sell Generic Lyrica In US  |  FDA Gets Device, But Not Drug Tracking  |  India’s Anti-Brand Stance Threatens Big Pharma Growth  |  U.K To Spend Less On Branded Drugs  |  EMA Provides Information For Maintenance on Human Medicines in Accordance with Article 57(2) Requirements  |  Unified Patent System For Europe Close But Not Done Deal  |  On Patenting & Pharma Pricing  |  Why India Needs To Back A New R&D Treaty  |  Indian Pharma Urges Govt Over US User Fees  |  European Parliament Rejects Anti Counterfeiting Trade Agreement  |  India Faces US Treat Over Cancer Drug Nexavar’s Generic Make  |  Committee of Secretaries To Look Into Pharma Issues  |  Govt. To Set Up Rs.2000- Crore Venture Fund For R&D In Pharma  |  Brazil Takes Control Over Its Pharma Market  |  US FDA Nod For Lupin’s Oral Pregnancy Pill  |  U.K. To Spend Less On Branded Drugs, Report Finds  |  Growth of Generics In Japan  |  China Puts Oversight Burden on Drug Makers  |  Dr Reddy’s Launches Ibandronate Sodium Tablets  |  USPTO Official Lambasts Issuance Of Compulsory Licensing By Indian Patent Office  |  EMA Revises Process Validation Guidelines, Insists On Data In Dossier Submission  |  Drug Patents Expiry To Give Generic Pharma Market Shot In Arm  |  Generic Antiviral Market Poised To Boom  |  Imminent Patent Expiry Of Key Blockbuster Drugs To Benefit Generic Manufacturers    |  Mylan Confirms First To File Patent Challenge Relating To Pristique Tablets  |  India Unveils Biosimilar Guidelines  |  India Pledges “Free Drugs For All” From October  |  New & Generic Drug Approvals at USFDA  |  Novartis battles Ranbaxy over generic Nexium  |  FDA Petitioned On 180 Day Exclusivity Forfeiture for Tentative Approvals That Occur On The 30-Month ANDA Submission Anniversary Date  |  Natco Pharma & Mylan To Appeal Against US Court Ruling On Teva’s Copaxone  |  MSF Appeals European Nations Not To Ratify Anti-Counterfeiting Trade Agreement  |  Indians Drug Cos Okay With US Law On Enhanced Inspection  |  US Govt Forecasts Sharp Slowdown in Drug Spending Growth  |  A Compulsory Licensing Spreads, Drug Makers Adapt  |  New & Generic apporvals at USFDA  |  New & Generic apporvals at USFDA  |  Merck loses Nasonex patent lawsuit against Apotex in US  |  Azad visits US FDA; stresses on importance of collaboration with US in food and drug regulation  |  Smaller Indian Drug Makers Need Support to Improve GMPs  |  Venus Remedies gets US Patent For Its New Antibiotic Product  |  Indian Pharma Companies Like Ranbaxy, Dr Reddy’s & Others eye $1bn Generic Opportunity  |  Bayer Files Patent on Manufacturing Process For Chewable Drug  |  Ranbaxy’s High on Lipitor to go on in US  |  Pharma companies need aggressive R&D and patent filing: Experts  |  US FDA to make QbD document mandatory for exporters from January 2013  |  US Body to Bring out Drug Reference Standards to Biologicals  |  China’s drug-law revamp rattles Big Pharma  |  China to license copies of patented medicines  |  China changes patent law in fight for cheaper drugs  |  The Manufacturing Plan-Strategies for Accelerating Growth of Manufacturing in India in the 12th Five Year Plan and Beyond  |  Two Big Wins for Generics Clarify Non-Infringement Strategies for Method of Use Patents  |  India needs more R&D in basic sciences to achieve success  |  Enforcement of Intellectual Property Rights on imported goods - Clarification on the issue of parallel imports – regarding  |  Merck Wins U.S. ZETIA (ezetimibe)/ VYTORIN (ezetimibe/simvastatin) Patent Infringement Lawsuit  |  Annual meeting shines light on ‘Golden Age of Medicine’  |  Federal judge sets dates for first two trials against Pfizer over Chantix stop-smoking drug  |  Marni Soupcoff: How cheaper drugs for everyone leads to hardly any drugs for anyone  |  Ampio Pharma gets patent for its lead drug Ampion from USPTO  |  Fuisz Pharma Announces Filing of Patent Application Relating to Breath-Based Diagnostics  |  AstraZeneca patent invalid, UK court rules  |  Global Pharmaceutical Contract Manufacturing Market to Reach US$26.14 Billion by 2017  |  Healthy competition can save lives through shared value  |  Shaping the biosimilars opportunity:A global perspective on the evolving biosimilars landscape  |  Pfizer wages war on fake drugs with mobile detectors  |  J&J Sold Vaginal Mesh Implant Without U.S. Regulatory Approval  |  FDA Decisions: Biotech Companies Waiting for FDA Approval  |  DGFT, Pharmexcil hold seminar to sensitize traders, industry bodies on dumping  |  Court backs Mayo in patent case  |  USFDA to inspect Dr Reddy’s Mexico facility in March  |  Litigation clouds Sun Pharmaceutical  |  List of new cases at US Federal Circuit as on 19th March 2012  |  India Affirms Role as Developing World’s Pharmacy  |  Ampio says eye drug shows promise in trial  |  White House OKs medical device act  |  Fall in number of patents filed by big pharma  |  Generic Pharmaceutical Manufacturing in the US Industry Market Research Report  |  TREAT Act would speed up drug approval process  |  Biotech Funding Gets Harder to Find  |  Biotech Funding Gets Harder to Find  |  Lundbeck’s alcoholism drug faces EU regulatory challenges  |  The Global Innovation Policy Index by ITIF and Kauffman Foundation, March 2012  |  Watson Confirms BYSTOLIC(R) Patent Challenge  |  Pharmaceutical & Healthcare Annual Deals Analysis 2012  |  India Patent Office Grants Compulsory License To Natco Pharma On Bayer Cancer Drug  |  Fake Avastin Shows Very Little Protects Drug Supply  |  Ranbaxy Labs: USFDA issues currency moves to shape future course  |  Ranbaxy Labs: USFDA issues, currency moves to shape future course  |  List of Indian Company Sites Registered by USFDA as on 31st Oct 2011  |  The Global Use of Medicines:Outlook Through 2015 as IMS Report  |  List of Pharmaceutical Patents/Market Exclusivity Expiry 2010-2030  |  INDIA-LAC Business Meet and Patent Awards 2011-Photos  |  Pharmexcil Patent Awards 2011-Flyer  |  Supreme Court Grants Cert In Mayo vs Prometheus  |  AstraZeneca loses ruling on patent for Nexium in Europe  |  AstraZeneca sues Lupin for 'infringing on' drug patent  |  EU blamed for breaking Doha Declaration denying access to cheaper medicines to poor nations  |  India takes lead for guiding developing countries to drive WHO focus onpublic health instead of IPR  |  Special Address by Mr Pascal Lamy, Director General, World Trade Organisation (WTO) on WTO and Doha Negotiations: Closing the Gaps and Moving Ahead at New Delhi on 19th November, 2010  |  Lupin sued in US over HIV drug  |  Boost for generic biz: SC rejects Bayer s petition  |  Brain League launches reference manual on Indian Patent Law & its Practice  |  Drug cos want IP issues kept out of pact with EU  |  A powerful push for US firms patent  |  Cadila banks on new markets to treble its revenue in 5 years  |  Now Merck sues Hetero Drugs over Finasteride  |  Roche Warner Chilcott sue Sun Pharma arm  |  Venus gets patent for antibiotic drug from Russia Ukraine  |  Lupin sued in US over skin drug patent violation  |  Pfizer drags DRL to court over Lipitor copy launch  |  Abbotts HIV drug patent plea rejected for lack of novelty  |  Lupin settles litigation in US  |  Dr Reddys to contest Pfizers patent suit over atorvastatin  |  EU push for liberal patents finds favour with PMO  |  Glenmark suffers setback in patent case against Abbott  |  Glenmark hit by adverse verdict  |  View more
Circulars: PHARMEXCIL- PATENT AWARDS 2012-13 |  National Intellectual Property Awards -2013-Notification released by Indian Patent Office |  Circular - Repeated with Revised Fee Particulars - Certificate Course on IPR (Patent) Matters - Five day Workshop at Hyderabad |  "Certificate Course on IPR (Patent) Matters" Five day workshop at Hyderabad in Jan 2013 |  List of WHOGMP/USFDA/MHRA/EDQM approved Indian Companies/Products |  Publication of Draft guidelines on traditional knowledge and Biological material with respect to processing of patent applications - released by Indian patent office-Last Date 29th Nov, 2012 |  Reminder Circular relating to Dialog Pro and Orbit Patent Databases for Pharmexcil members – reg |  Free trial for ten days of Orbit Patent Database for Pharmexcil Members-Reg |  Extension of Last Date for receipt of application for Pharmexcil Export & Patent Awards 2011-12 |  Seminar on IPR & Regulatory Matters in Pharmaceutical Sector at Chennai on 24th August, 2012 (Friday) |  Awards for companies who secured patents during April 2011-March 2012 |  Seminar on IPR & Regulatory Matters in Pharmaceutical Sector at Ahmedabad on 26th July, 2012 (Thursday) |  Seminar on IPR & Regulatory Matters in Pharmaceutical Sector at Mumbai on 22nd June, 2012 (Friday)-Reg |  Seminar on IPR & Regulatory Matters in Pharmaceutical Sector at Hyderabad on 23rd May, 2012 (Wednesday)-Reg |  IPR/Patent/R&D Departments-Availability of Orbit/Dialog Pro Patent Database at Pharmexcil offices Attention: IPR/Patent/R&D Departments-Availability of Orbit/Dialog Pro Patent Database at Pharmexcil offices |  List of USFDA approved Inactive ingredients/excipients for various dosage forms |  List of Pharmaceutical Patents/Market Exclusivity Expiry 2010-2030 |  BLOCK YOUR DATES-Pharmexcil Patent and Export Awards-INDIA-LAC PHARMA BUSINESS MEET |  Extension of Last Date for Submission of Applications for Pharmexcil Outstanding Export and Patent Awards, 2011 to 16th August, 2011 |  Awards for companies who secured patents during April 2010-March 2011 |  Interctive Sessions Presentation on US Patent Law and its Impact on Indian Pharma Industry |  Export Promotion and Patents Awareness Seminar at Bangalore on 18th November, 2010 |  Seminar cum Interactive session on GLP, eCTD & Patent Awareness, on 24th November, 2010 at Ahmedabad. |  Interactive session with Dr. Prof. Frederick M. Abbott, Panelist-WTO and Senior Officers |  Part reimbursement of fee for employees of the member companies of Pharmexcil who secured certificate/Diploma on IPR/Patents offered by institutions/universities during the academic year 2008-09 and 2009-10  |  PATENTS ALERT TO CPhI PARTICIPANTS |  Pharma Conclave & Conferral of Export, Patent Awards |  Extension of Last Date for Submission of Applications for Pharmexcil Outstanding Export Awards 2010 and Patent Awards 2010 to 15.9.2010 |  Request for Contact Information of Patent Research Heads – Reg. |  Patent Awareness Seminar at Hyderabad on 31st August, 2010  |  Awards for companies who secured patents during April 2009-March 2010 |  Global Conclave of CEOs of Pharma Industry on 24th September 2010 at Hyderabad. |  INDIAN GRANTED PATENTS INFORMATION. |  MONTHLY ANALYSIS OF INDIAN GRANTED PATENTS |  PATENTS AWARENESS PROGRAMME AT MUMBAI  |  PATENT AWARENESS SEMINAR AT MUMBAI |  PHARMEXCIL NEWS COMPILATION |  Indian Granted Patents in Health Care Sector during April - September 2009 - Monthly analysis |  ISSUES RELATED PATENTS VIOLATIONS IN EUROPE |  INAUGURATION OF PATENTS FACILITATION CENTRE AT MUMBAI |  INVITATION CIRCULAR ? 83 |  INAUGURATION OF PATENTS FACILITATION CENTER, HYDERABAD |  PATENTS FACILITATION CENTER AT HYDERABAD CIRCULAR ? 33 |  PATENTS INFORMATION CIRCULAR ? 58 |  INDIAN PATENT AWARDS IN DRUGS & PHARMACEUTICAL SECTOR - MONTHLY ANALYSIS |  View more
Our Services
Statistics on Bulk Drugs/Formulations-Approved/Imported/Marketed/Registered in India
Statistics on Patent Applications/Granted at Indian Patent Office
IPR & Regulatory Centre
The main objective of the centre is to promote awareness and extend supporting services on IPR issues (Patents) in Indian Pharmaceutical Sector and particularly w.r.t international marketing. In order to meet the above objective centre is undertaking several activities
Avail Pharmexcil IPR & RC Services
Pharmexcil is keen to help all pharmaceutical companies on issues relating to IPRs/Patents. We invite all Indian companies to contact us for any clarification/suggestions on this subject.

Please read the circular issued by Pharmexcil to its members for detailed information regarding our services.

Entire correspondence on the subject shall be kept strictly confidential.
News and Events
USFDA Approved Drug Products
IPR & Regulatory Centre
Statistics on Patent Applications/Granted at Indian Patent Office
List of Drugs
Health Canada As on 8th Mar 2013
Health Canada As on 8th Mar 2013
Pharmexcil Award Export & Patent Awards 2012-Catalogue Pharmexcil's Research Paper Publications List of Drug Master Filings at USFDA
Pharmexcil Home  l  IPR & RC Home  l  About Us  l  Events  l  Feedback  l  Contact Us   l  Pharmexcil Circulars on IPRs  l  Useful Websites  l  Glossary
Copyright © 2009 Pharmexcil. All rights reserved.
Powered by: iBongo Inc